Literature DB >> 32789760

Guanosine Neuroprotection of Presynaptic Mitochondrial Calcium Homeostasis in a Mouse Study with Amyloid-β Oligomers.

Jussemara Souza da Silva1, Yasmine Nonose1, Francieli Rohden1, Pâmela C Lukasewicz Ferreira1, Fernanda Urruth Fontella1, Andréia Rocha1, Andressa Wigner Brochier1, Rodrigo Vieira Apel1, Thais Martins de Lima1, Bianca Seminotti1, Alexandre Umpierrez Amaral1,2, Antonio Galina3, Diogo O Souza4.   

Abstract

Amyloid-β oligomers (AβOs) toxicity causes mitochondrial dysfunction, leading to synaptic failure in Alzheimer's disease (AD). Considering presynaptic high energy demand and tight Ca2+ regulation, impairment of mitochondrial function can lead to deteriorated neural activity and cell death. In this study, an AD mouse model induced by ICV (intracerebroventricular) injection of AβOs was used to investigate the toxicity of AβOs on presynaptic function. As a therapeutic approach, GUO (guanosine) was given by oral route to evaluate the neuroprotective effects on this AD model. Following 24 h and 48 h from the model induction, behavioral tasks and biochemical analyses were performed, respectively. AβOs impaired object recognition (OR) short-term memory and reduced glutamate uptake and oxidation in the hippocampus. Moreover, AβOs decreased spare respiratory capacity, reduced ATP levels, impaired Ca2+ handling, and caused mitochondrial swelling in hippocampal synaptosomes. Guanosine crossed the BBB, recovered OR short-term memory, reestablished glutamate uptake, recovered mitochondrial Ca2+ homeostasis, and partially prevented mitochondrial swelling. Therefore, this endogenous purine presented a neuroprotective effect on presynaptic mitochondria and should be considered for further studies in AD models.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-β oligomers; Guanosine; Neuroprotection; Presynaptic mitochondria

Mesh:

Substances:

Year:  2020        PMID: 32789760     DOI: 10.1007/s12035-020-02064-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  3 in total

1.  Guanosine ameliorates positive symptoms of schizophrenia via modulating 5-HT1A and 5-HT2A receptors.

Authors:  Yu Mao; Yao Xing; Jie Li; Dong Dong; Shoude Zhang; Zhenjiang Zhao; Jingli Xie; Rui Wang; Honglin Li
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Guanosine Mechanisms of Action: Toward Molecular Targets.

Authors:  Caio M Massari; Mariachiara Zuccarini; Patrizia Di Iorio; Carla I Tasca
Journal:  Front Pharmacol       Date:  2021-03-31       Impact factor: 5.810

Review 3.  Protection against Amyloid-β Oligomer Neurotoxicity by Small Molecules with Antioxidative Properties: Potential for the Prevention of Alzheimer's Disease Dementia.

Authors:  Wataru Araki; Fuyuki Kametani
Journal:  Antioxidants (Basel)       Date:  2022-01-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.